Primary pulmonary hypertension and its management;Hipertensión pulmonar primaria y su tratamiento

Farmacia Hospitalaria

Volumn 28, Issue 1, 2004, Pages 48-55

  Crespo Martínez, Cristina ^a   Morales Leon M ^a   Alonso Ramos, H ^a   Alonso Ortiz, B ^a   Molero Gomez R ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Bosentan; Nitric oxide; Prostacyclin; Pulmonary hypertension; Sildenafil

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; SILDENAFIL; UNIPROST; VASODILATOR AGENT;

HUMAN; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; PATHOGENESIS; PULMONARY HYPERTENSION; REVIEW; THROMBOSIS; VASOCONSTRICTION;

AMPHETAMINES; CARDIOVASCULAR AGENTS; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; NITRIC OXIDE; PIPERAZINES; PROSTAGLANDINS I; PULMONARY ARTERY; RECEPTORS, ENDOTHELIN; THROMBOSIS; VASOCONSTRICTION;

EID: 2142819606     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. a. Ed. Mosby/Doyma Libros, 1998. p. 956-8.
2. Carey CF, Lee HH, Woeltje KF. Manual Washington de terapéutica médica. 10 ed. 1999.
3. MD Consult. Clinical Topic Tours 28 Aug 2002. Primary Pulmonary Hypertension. (http://www.home.mdconsult.com/das/stat/view/25507836/ctt?nid=84496&sid= 156191025)
4. th ed., 2001. p. 1912-28.
5. Olsckewski H, Rose F, Grunig E, Ghofrani HA, Walmrath D, Schulz R, et al. Cellular pathophysiology and therapy of pulmonary hipertension. J Lab Clin Med 2001; 138 (6): 367-77.
6. Newman JH. Treatment of primary pulmonary hypertension- the next generation. N Eng Med 2002; 346: 933-5.
7. Barbera JA. Nueva nomenclatura y clasificación de la hipertensión pulmonar primaria. Arch Bronconeumol 2002; 38 (S1): 3-9.
8. Santos S, Peinado VI. Conceptos actuales sobre la patogenia de la hipertensión pulmonar primaria. Arch Bronconeumol 2002; 38 (S1): 10-5.
9. Channick RN, Rubin LJ. New and experimental therapies for pulmonary hipertensión. Clin Chest Med 2001; 22 (3): 539-45.
10. Regional Drug and Therapeutics Centre. The use of iloprost and epoprostenol in the management of pulmonary hypertension. NHS Northern and Yorkshire. 2001: 1-29. (http://www.ukmi.nhs.uk).
11. Barst RJ. Medical therapy of pulmonary hypertension. Clin Chest Med 2001; 22 (3): 509-15.
12. Lobo JL. Pauta de tratamiento de la hipertensión pulmonar. Arch Bronconeumol 2002; 38 (S1): 24-8.
13. Frank, H, Mlczoch, J, Huber, K, et al. The effect of anticoagulant therapy in primary and anoretic drug-induced pulmonary hipertensión. Chest 1997; 112: 714.
14. Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coagul Fibrinolysis 1998; 9: 107-17.
15. UptoDate 9.1. Treatment of primary pulmonary hipertensión. Rubin JL.
16. Barberá JA. Nueva nomenclatura y clasificación de la hipertensión pulmonar. Arch Brononeumol 2002; 38 (S1): 3-9.
17. Newman JH. Treatment of primary pulmonary hypertension the next generation. N Eng Med 2002; 346: 933-5.
18. Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001; 22 (3): 529-37.
19. Fishman AP. Epoprostenol (Prostacyclin) and Pulmonary Hypertension. Ann Intern Med 2000; 132: 500-2.
20. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuos intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-91.
21. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension Study Group. N Engl J Med 1996; 334: 296-302.
22. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (protacyclin) therapy in primary pulmonary hipertensión. N Engl J Med 1998; 338: 237-77.
23. Gómez MA, Lázaro M, Escribano P, Delgado JF, Tello R, Cea L, et al. Nuevos tratamientos médicos. Arch Brononeumol 2002; 38 (S1): 29-32.
24. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long-Term treatment of primary pulmonary hipertensión with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342 (25): 1866-70.
25. Schenk P, Petkov V, Madl C, Kramer L, Kneussl M, Ziesche R, et al. Aerosolized iloprost therapy could not replace long-term IV epoprostenol prostacyclin administration in severe pulmonary hypertension. Chest 2001; 119: 296-300.
26. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hipertensión. Ann Intern Med 1996; 124 (9): 820-4.
27. Pérez-Peñate G, Juliá GJ, Pulido JM, Górriz E, Cabrera P. One-year continuous inhaled nitric oxide for primary pulmonary hypertension. Chest 2001; 119 (3): 970-4.
28. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991; 338: 1173-4.
29. Olsckewski H, Rose F, Grunig E, Ghofrani HA, Walmrath D, Schulz R, et al. Cellular pathophysiology and therapy of pulmonary hipertensión. J Lab Clin Med 2001; 138 (6): 367-77.
30. Ricciardi MJ, Knight BP, Martínez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hipertensión: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 2001; 38 (4): 1267-8.
31. Ziesche R, Petkov V, Wittmann K, Kopatschka J, Stiebellehner L, Schenk P, et al. Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension. Heart 2000; 83: 406-9.
32. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343:1342 Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, et al. Sildenafil inhibits Hypoxia-induced pulmonary hipertensión. Circulation 2001; 104: 424-8.
33. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343:1342 Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, et al. Sildenafil inhibits Hypoxia-induced pulmonary hipertensión. Circulation 2001; 104: 424-8.
34. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, et al. Sildenafil inhibits Hypoxia-induced pulmonary hipertension. Circulation 2001; 104: 424-8.
35. Michelais E, Tymchak W, Lien D, Webtser L, Hashimoto K, Archer S. Oral sildenafl is an effective and specific pulmonary vasodilatador in patiens with pulmonary arterial hypertension. Circulation 2002; 105: 2398-403.
36. Ghofrani HA, Wiedemann R, Rose F, Olscewski H, Schermuly RT, Weissmann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-22.
37. Wilkens H, Guth A, König J, Forestier N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patiens with primary pulmonary hypertension. Circulation 2001; 104: 1218-22.
38. Ussetti P, Varela A. Alternativas quirúrgicas en el tratamiento de la hipertensión pulmonar grave. Arch Bronconeumol 2002; 38 (S1): 33-8.